2016
Treatment for Multiple Acute Cardiopulmonary Conditions in Older Adults Hospitalized with Pneumonia, Chronic Obstructive Pulmonary Disease, or Heart Failure
Dharmarajan K, Strait KM, Tinetti ME, Lagu T, Lindenauer PK, Lynn J, Krukas MR, Ernst FR, Li SX, Krumholz HM. Treatment for Multiple Acute Cardiopulmonary Conditions in Older Adults Hospitalized with Pneumonia, Chronic Obstructive Pulmonary Disease, or Heart Failure. Journal Of The American Geriatrics Society 2016, 64: 1574-1582. PMID: 27448329, PMCID: PMC4988873, DOI: 10.1111/jgs.14303.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAged, 80 and overAnti-Bacterial AgentsCardiotonic AgentsCohort StudiesComorbidityCross-Sectional StudiesDiureticsDrug Therapy, CombinationFemaleHeart FailureHospitalizationHumansMalePneumoniaPulmonary Disease, Chronic ObstructiveRetrospective StudiesUnited StatesVasodilator AgentsConceptsChronic obstructive pulmonary diseaseAcute cardiopulmonary conditionsObstructive pulmonary diseaseHeart failureCardiopulmonary conditionsOlder adultsPulmonary diseasePremier Research DatabaseEpisodes of pneumoniaRetrospective cohort studyReal-world treatmentHF hospitalizationCohort studyHospital daysPneumonia hospitalizationsCOPD hospitalizationsClinical syndromeAcute conditionsPneumoniaDiagnostic uncertaintyResearch DatabaseHospitalizationDiagnostic categoriesU.S. hospitalsAdultsAvailability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials
Murugiah K, Ritchie JD, Desai NR, Ross JS, Krumholz HM. Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials. Journal Of The American Heart Association 2016, 5: e003307. PMID: 27098969, PMCID: PMC4859296, DOI: 10.1161/jaha.116.003307.Peer-Reviewed Original ResearchConceptsIndividual participant-level dataLarge cardiovascular trialsCardiovascular trialsParticipant-level dataClinical trial dataPharmaceutical companiesMajor pharmaceutical companiesIndustry-sponsored clinical trialsInterventional trialsAvailable trialsClinical trialsTrial dataTrialsPatientsSpecific reasons
2014
Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure
Allen LA, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Peterson PN, Partovian C, Li SX, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure. Circulation Heart Failure 2014, 7: 251-260. PMID: 24488983, PMCID: PMC5459367, DOI: 10.1161/circheartfailure.113.000761.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiotonic AgentsCross-Sectional StudiesDose-Response Relationship, DrugFemaleFollow-Up StudiesGuideline AdherenceHeart FailureHospital MortalityHospitalsHumansInfusions, IntravenousInpatientsLength of StayMaleOutcome Assessment, Health CarePractice Patterns, Physicians'RegistriesRetrospective StudiesSurvival RateUnited StatesConceptsInotrope useHeart failureInotropic therapyInotropic agentsGuidelines-Heart Failure registryIntravenous inotropic agentsIntravenous inotropic therapyRisk-standardized ratesUse of inotropesHeart failure hospitalizationHospital-level ratesRandom hospital effectsFailure hospitalizationClinical characteristicsHospital factorsInpatient mortalityClinical factorsClinical outcomesHospital variationHospital characteristicsHospital effectsPatientsUS hospitalsHospitalStudy period
2013
Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure
Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM. Contraindicated Initiation of β-Blocker Therapy in Patients Hospitalized for Heart Failure. JAMA Internal Medicine 2013, 173: 1547-1549. PMID: 23797379, PMCID: PMC4043342, DOI: 10.1001/jamainternmed.2013.7717.Peer-Reviewed Original Research
2012
Hospital Patterns of Use of Positive Inotropic Agents in Patients With Heart Failure
Partovian C, Gleim SR, Mody PS, Li SX, Wang H, Strait KM, Allen LA, Lagu T, Normand SL, Krumholz HM. Hospital Patterns of Use of Positive Inotropic Agents in Patients With Heart Failure. Journal Of The American College Of Cardiology 2012, 60: 1402-1409. PMID: 22981548, PMCID: PMC3636773, DOI: 10.1016/j.jacc.2012.07.011.Peer-Reviewed Original ResearchConceptsPositive inotropic agentsRisk-standardized ratesInotropic agentsHeart failureInotrope useHospital patternsMortality rateRisk-standardized mortality ratesHospital mortality rateHeart failure patientsLittle clinical evidenceLength of stayPatient case mixHierarchical logistic regression modelsLogistic regression modelsIntraclass correlation coefficientFailure patientsHospital variationClinical evidenceInterhospital variationClinical guidelinesIndividual hospital effectsHospital ratesHospital effectsPatterns of use
2004
Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial
SHLIPAK MG, SMITH GL, RATHORE SS, MASSIE BM, KRUMHOLZ HM. Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial. Journal Of The American Society Of Nephrology 2004, 15: 2195-2203. PMID: 15284305, DOI: 10.1097/01.asn.0000135121.81744.75.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateHeart failure outcomesEffect of digoxinRenal functionHeart failureRenal dysfunctionGroup trialsMortality riskLow glomerular filtration rateLevel of GFRFailure outcomesSystolic heart failureHeart failure survivalLower mortality hazardDigoxin efficacyCause mortalityDigoxin therapyCommon complicationClinical outcomesFiltration rateGFR 60Failure survivalSimilar riskMortality hazardStable outpatients
2003
Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure
Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure. JAMA 2003, 290: 81-85. PMID: 12837715, DOI: 10.1001/jama.290.1.81.Peer-Reviewed Original ResearchConceptsHeart failureDiabetic patientsConcomitant diabetesThiazolidinedione useMedicare beneficiariesRetrospective medical record abstractionUse of metforminAdvanced heart failureProportion of patientsHeart failure therapyMedical record abstractionAcute care hospitalsMetformin useFailure therapyHospital dischargeCare hospitalRecord abstractionOptimal carePrimary diagnosisAntihyperglycemic drugsMedicare patientsDrug treatmentPatterns of usePatientsPackage insertsDigoxin therapy for heart failure: safe for women?
Rathore SS, Krumholz HM. Digoxin therapy for heart failure: safe for women? Journal Of Cardiovascular Medicine 2003, 4: 148-51. PMID: 12784740.Peer-Reviewed Original ResearchAssociation of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure. JAMA 2003, 289: 871-878. PMID: 12588271, DOI: 10.1001/jama.289.7.871.Peer-Reviewed Original ResearchConceptsSerum digoxin concentrationHigh serum digoxin concentrationsLeft ventricular ejection fractionVentricular ejection fractionHeart failureMortality rateDIG trialDigoxin therapyEjection fractionDigoxin concentrationsDepressed left ventricular systolic functionDigitalis Investigation Group trialHigher absolute mortality rateLeft ventricular systolic functionOverall mortality benefitVentricular systolic functionCause mortality ratesAbsolute mortality ratesLower mortality rateCause mortalityMultivariable adjustmentMortality benefitSystolic functionClinical outcomesSerum concentrations
2002
Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure
Rathore SS, Wang Y, Krumholz HM. Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure. New England Journal Of Medicine 2002, 347: 1403-1411. PMID: 12409542, DOI: 10.1056/nejmoa021266.Peer-Reviewed Original ResearchConceptsEffect of digoxinDepressed left ventricular systolic functionLeft ventricular systolic functionVentricular systolic functionSex-based differencesRate of deathDigoxin therapyHeart failureSystolic functionMultivariable Cox proportional hazards modelsDigitalis Investigation Group (DIG) studyDigitalis Investigation Group trialCox proportional hazards modelHeart failure variesPrimary end pointRisk of deathProportional hazards modelMantel-Haenszel testOverall mortalityTherapy differsEpidemiologic featuresMultivariable analysisClinical variablesSubgroup analysisGroup trials